Lv5
840 积分 2023-05-06 加入
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
18天前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
18天前
已完结
MEN1 mutations mediate clinical resistance to menin inhibition
22天前
已完结
Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China
29天前
已完结
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
1个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
3个月前
已完结
The antibody–drug conjugate landscape
3个月前
已完结
The therapeutic window of antibody drug conjugates: A dogma in need of revision
4个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4个月前
已完结
皖公网安备34019202002308
